Rahul Aggarwal

Rahul Aggarwal is Associate Director for Clinical Sciences at the UCSF Helen Diller Family Comprehensive Cancer Center. A medical oncologist specialising in prostate cancer, neuroendocrine prostate cancer and PSMA theranostics, he leads UCSF's early-phase and prostate cancer clinical research and defined treatment-emergent small-cell neuroendocrine prostate cancer, the way tumours transform to escape hormone therapy. His papers include a multi-institutional prospective study characterising that disease clinically and genomically, and a report on heterogeneous flare in PSMA PET tracer uptake after starting androgen pathway blockade. He leads PSMA radioligand and combination trials, including with lutetium-177 vipivotide tetraxetan.